PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations

Proceedings of the National Academy of Sciences of the United States of America
Helen Y ZouValeria R Fantin

Abstract

Oncogenic c-ros oncogene1 (ROS1) fusion kinases have been identified in a variety of human cancers and are attractive targets for cancer therapy. The MET/ALK/ROS1 inhibitor crizotinib (Xalkori, PF-02341066) has demonstrated promising clinical activity in ROS1 fusion-positive non-small cell lung cancer. However, emerging clinical evidence has shown that patients can develop resistance by acquiring secondary point mutations in ROS1 kinase. In this study we characterized the ROS1 activity of PF-06463922, a novel, orally available, CNS-penetrant, ATP-competitive small-molecule inhibitor of ALK/ROS1. In vitro, PF-06463922 exhibited subnanomolar cellular potency against oncogenic ROS1 fusions and inhibited the crizotinib-refractory ROS1(G2032R) mutation and the ROS1(G2026M) gatekeeper mutation. Compared with crizotinib and the second-generation ALK/ROS1 inhibitors ceritinib and alectinib, PF-06463922 showed significantly improved inhibitory activity against ROS1 kinase. A crystal structure of the PF-06463922-ROS1 kinase complex revealed favorable interactions contributing to the high-affinity binding. In vivo, PF-06463922 showed marked antitumor activity in tumor models expressing FIG-ROS1, CD74-ROS1, and the CD74-ROS1(G2032R) mutati...Continue Reading

References

Jun 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·C BirchmeierM Wigler
Nov 14, 1997·Neuroscience and Biobehavioral Reviews·J H McDonough, T M Shih
Dec 15, 2000·Oncogene·D R RobinsonS F Lin
Nov 15, 2001·Proceedings of the National Academy of Sciences of the United States of America·A BhattacharjeeM Meyerson
Nov 15, 2001·Proceedings of the National Academy of Sciences of the United States of America·M E GarberI Petersen
Jan 23, 2003·Proceedings of the National Academy of Sciences of the United States of America·Alan CharestDavid Housman
Mar 28, 2003·Genes, Chromosomes & Cancer·Alain CharestDavid Housman
Apr 16, 2003·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Donald E MagerWilliam J Jusko
Mar 8, 2008·Current Opinion in Genetics & Development·Jeffrey A Engelman, Jeffrey Settleman
Sep 10, 2008·Biochimica Et Biophysica Acta·Jaime AcquavivaAl Charest
Jul 16, 2009·Genesis : the Journal of Genetics and Development·Steve WoolfendenAl Charest
Jan 5, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kristin BergethonA John Iafrate
Feb 14, 2012·Nature Medicine·Kengo TakeuchiYuichi Ishikawa
Apr 17, 2012·Expert Review of Anticancer Therapy·Sai-Hong Ignatius OuRoss A Soo
Jun 5, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Victoria M RimkunasHerbert Haack
Aug 23, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Johannes M HeuckmannRoman K Thomas
Sep 15, 2012·Genome Research·Jeong-Sun SeoYoung Tae Kim
Feb 13, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alice T Shaw, Jeffrey A Engelman
Jun 4, 2013·The New England Journal of Medicine·Mark M AwadAlice T Shaw
Jul 28, 2013·The American Journal of Surgical Pathology·Lynette M ShollScott J Rodig
Oct 9, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Justin F Gainor, Alice T Shaw
Nov 13, 2013·Proceedings of the National Academy of Sciences of the United States of America·Monika A DavareBrian J Druker
Jan 22, 2014·Nature Communications·Thomas WiesnerBoris C Bastian
Mar 29, 2014·Cancer Discovery·Luc FribouletJeffrey A Engelman
Apr 17, 2014·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Sai-Hong Ignatius OuVincent A Miller
May 31, 2014·Cancer Discovery·Christine M LovlyCheryl M Coffin
Jul 31, 2014·The Journal of Pharmacology and Experimental Therapeutics·Shinji YamazakiPaolo Vicini
Sep 11, 2014·Nature Communications·Nicolas StranskyChristoph Lengauer
Sep 30, 2014·The New England Journal of Medicine·Alice T ShawA John Iafrate
Oct 30, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ryohei KatayamaNaoya Fujita
Feb 12, 2015·The New England Journal of Medicine·Alice T Shaw, Benjamin J Solomon
Feb 18, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ahnah SongDae Seog Heo

❮ Previous
Next ❯

Citations

Oct 21, 2015·Expert Review of Anticancer Therapy·Paola Claudia SaccoCesare Gridelli
Dec 15, 2015·Expert Review of Anticancer Therapy·Ittai B MullerGodefridus J Peters
Nov 4, 2015·Cancer Biology & Therapy·Zhihong ZhaoMutian Zhang
Nov 29, 2015·Seminars in Oncology·Keara L RedmondSandra Van Schaeybroeck
Mar 26, 2016·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Anne S TsaoHarvey I Pass
May 21, 2016·Frontiers in Oncology·Pranshu BansalYanis Boumber
Apr 26, 2016·Expert Review of Anticancer Therapy·Alessandro RussoVincenzo Adamo
Oct 23, 2016·Clinical Lung Cancer·Alexios MatikasAthanasios Kotsakis
Aug 31, 2016·Lancet·Fred R HirschLuis Paz-Ares
Oct 4, 2016·Journal of Molecular Graphics & Modelling·Disha PathakOm Silakari
Mar 21, 2017·Journal of Chemical Information and Modeling·Yuanxin TianJiajie Zhang
May 19, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ibiayi Dagogo-Jack, Alice T Shaw
Sep 1, 2017·Nature Reviews. Clinical Oncology·Alison M SchramAlexander Drilon
Aug 9, 2017·Clinical Pharmacology and Therapeutics·Manasi K Mayekar, Trever G Bivona
Dec 1, 2017·Expert Review of Anticancer Therapy·Assunta SgambatoCesare Gridelli
Jul 3, 2018·Future Medicinal Chemistry·Siming LiuJiajie Zhang
Jan 19, 2019·Expert Review of Clinical Pharmacology·Junyi Yang, Weiliang Gong
Jul 23, 2016·Molecular Medicine·Havva O KilgozBahar Taneri
Mar 5, 2020·Expert Opinion on Therapeutic Patents·Justin J BaileyRalf Schirrmacher
Mar 5, 2016·Oncotarget·Fabrizio TabbòGiorgio Inghirami
Apr 1, 2020·Expert Review of Anticancer Therapy·Andrea Sartore-BianchiSalvatore Siena
Aug 10, 2018·JCI Insight·Suchita Pakkala, Suresh S Ramalingam
Jul 1, 2019·Cancer Chemotherapy and Pharmacology·Annie RoysDaiying Zuo
Dec 8, 2016·Journal of Hematology & Oncology·Bao Quoc LamZhiqiang Qin

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.